Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson's disease.

After 6 weeks of dosing, we found that PTC-041 did not alter the robust increase in total α-synuclein observed, but it induced a marked trend towards reduction in aggregated and phosphorylated α-synuclein ( Fig 8A and 8B ). •To evaluate the effect of PTC-041 on neuronal viability in older mice, a separate study was conducted wherein 6-week-old transgenic Line 61 mice were dosed with PTC-041 daily for 15 weeks.

also in 135 other papers